Oral fondaparinux: use of lipid nanocapsules as nanocarriers and in vivo pharmacokinetic study

Alyaa Ramadan1,4, Frederic Lagarce1,3, Anne Tessier-Marteau2, Olivier Thomas1, Pierre Legras5, Laurent Macchi2, Patrick Saulnier1, Jean Pierre Benoit1,31LUNAM Université, Ingénierie de la Vectorisation Particulaire, Inserm U-646, Angers, France; 2Hematology Department,...

Full description

Bibliographic Details
Main Authors: Ramadan A, Lagarce F, Tessier-Marteau A, Thomas O, Legras P, Macchi L, Saulnier P, Benoit JP
Format: Article
Language:English
Published: Dove Medical Press 2011-11-01
Series:International Journal of Nanomedicine
Online Access:http://www.dovepress.com/oral-fondaparinux-use-of-lipid-nanocapsules-as-nanocarriers-and-in-viv-a8700
id doaj-1375d1ca280b41f7b0ea481e1a752324
record_format Article
spelling doaj-1375d1ca280b41f7b0ea481e1a7523242020-11-24T23:44:27ZengDove Medical PressInternational Journal of Nanomedicine1176-91141178-20132011-11-012011default29412951Oral fondaparinux: use of lipid nanocapsules as nanocarriers and in vivo pharmacokinetic studyRamadan ALagarce F, Tessier-Marteau AThomas OLegras P, Macchi LSaulnier PBenoit JPAlyaa Ramadan1,4, Frederic Lagarce1,3, Anne Tessier-Marteau2, Olivier Thomas1, Pierre Legras5, Laurent Macchi2, Patrick Saulnier1, Jean Pierre Benoit1,31LUNAM Université, Ingénierie de la Vectorisation Particulaire, Inserm U-646, Angers, France; 2Hematology Department, Angers University Hospital, Angers, France; 3Department of Pharmacy, Angers University Hospital, Angers, France; 4Department of Pharmaceutics, Faculty of Pharmacy, Alexandria University, Alexandria, Egypt; 5SCAHU, Animal House, Angers, FranceAbstract: Oral anticoagulant therapy could be advanced using lipid-based nanoparticulate systems. This study examined lipid nanocapsules for their oral absorption potential as the first step in developing oral fondaparinux (Fp) novel carriers. Using phase inversion method and cationic surfactants such as hexadecyltrimethyl ammonium bromide (CTAB) or stearylamine (SA), cationic lipid nanocapsules (cLNCs), loaded with Fp on their surface, were prepared and characterized (zeta potential, size and Fp association efficiency and content). In vivo studies were conducted after single oral increasing doses of Fp-loaded cLNCs (0.5 to 5 mg/kg of Fp) in rats and the concentration of Fp in the plasma was measured by anti-factor Xa activity assay. The monodisperse, (~50 nm), positively charged Fp-cLNCs with high drug loadings demonstrated linear pharmacokinetic profiles of the drug with an increased oral absolute bioavailability (up to ~21%) compatible with therapeutic anticoagulant effect (>0.2 µg/mL).Keywords: oral anticoagulant, fondaparinux, lipid nanocapsules, bioavailability, pharmacokinetics, ratshttp://www.dovepress.com/oral-fondaparinux-use-of-lipid-nanocapsules-as-nanocarriers-and-in-viv-a8700
collection DOAJ
language English
format Article
sources DOAJ
author Ramadan A
Lagarce F, Tessier-Marteau A
Thomas O
Legras P, Macchi L
Saulnier P
Benoit JP
spellingShingle Ramadan A
Lagarce F, Tessier-Marteau A
Thomas O
Legras P, Macchi L
Saulnier P
Benoit JP
Oral fondaparinux: use of lipid nanocapsules as nanocarriers and in vivo pharmacokinetic study
International Journal of Nanomedicine
author_facet Ramadan A
Lagarce F, Tessier-Marteau A
Thomas O
Legras P, Macchi L
Saulnier P
Benoit JP
author_sort Ramadan A
title Oral fondaparinux: use of lipid nanocapsules as nanocarriers and in vivo pharmacokinetic study
title_short Oral fondaparinux: use of lipid nanocapsules as nanocarriers and in vivo pharmacokinetic study
title_full Oral fondaparinux: use of lipid nanocapsules as nanocarriers and in vivo pharmacokinetic study
title_fullStr Oral fondaparinux: use of lipid nanocapsules as nanocarriers and in vivo pharmacokinetic study
title_full_unstemmed Oral fondaparinux: use of lipid nanocapsules as nanocarriers and in vivo pharmacokinetic study
title_sort oral fondaparinux: use of lipid nanocapsules as nanocarriers and in vivo pharmacokinetic study
publisher Dove Medical Press
series International Journal of Nanomedicine
issn 1176-9114
1178-2013
publishDate 2011-11-01
description Alyaa Ramadan1,4, Frederic Lagarce1,3, Anne Tessier-Marteau2, Olivier Thomas1, Pierre Legras5, Laurent Macchi2, Patrick Saulnier1, Jean Pierre Benoit1,31LUNAM Université, Ingénierie de la Vectorisation Particulaire, Inserm U-646, Angers, France; 2Hematology Department, Angers University Hospital, Angers, France; 3Department of Pharmacy, Angers University Hospital, Angers, France; 4Department of Pharmaceutics, Faculty of Pharmacy, Alexandria University, Alexandria, Egypt; 5SCAHU, Animal House, Angers, FranceAbstract: Oral anticoagulant therapy could be advanced using lipid-based nanoparticulate systems. This study examined lipid nanocapsules for their oral absorption potential as the first step in developing oral fondaparinux (Fp) novel carriers. Using phase inversion method and cationic surfactants such as hexadecyltrimethyl ammonium bromide (CTAB) or stearylamine (SA), cationic lipid nanocapsules (cLNCs), loaded with Fp on their surface, were prepared and characterized (zeta potential, size and Fp association efficiency and content). In vivo studies were conducted after single oral increasing doses of Fp-loaded cLNCs (0.5 to 5 mg/kg of Fp) in rats and the concentration of Fp in the plasma was measured by anti-factor Xa activity assay. The monodisperse, (~50 nm), positively charged Fp-cLNCs with high drug loadings demonstrated linear pharmacokinetic profiles of the drug with an increased oral absolute bioavailability (up to ~21%) compatible with therapeutic anticoagulant effect (>0.2 µg/mL).Keywords: oral anticoagulant, fondaparinux, lipid nanocapsules, bioavailability, pharmacokinetics, rats
url http://www.dovepress.com/oral-fondaparinux-use-of-lipid-nanocapsules-as-nanocarriers-and-in-viv-a8700
work_keys_str_mv AT ramadana oralfondaparinuxuseoflipidnanocapsulesasnanocarriersandinvivopharmacokineticstudy
AT lagarcefampnbsptessiermarteaua oralfondaparinuxuseoflipidnanocapsulesasnanocarriersandinvivopharmacokineticstudy
AT thomaso oralfondaparinuxuseoflipidnanocapsulesasnanocarriersandinvivopharmacokineticstudy
AT legraspampnbspmacchil oralfondaparinuxuseoflipidnanocapsulesasnanocarriersandinvivopharmacokineticstudy
AT saulnierp oralfondaparinuxuseoflipidnanocapsulesasnanocarriersandinvivopharmacokineticstudy
AT benoitjp oralfondaparinuxuseoflipidnanocapsulesasnanocarriersandinvivopharmacokineticstudy
_version_ 1725498446723416064